Clinical Outcomes of Reintroducing Oxaliplatin to Patients with Colorectal Cancer after Mild Hypersensitivity Reactions

Publisher： Karger

E-ISSN： 1423-0232|85|6|323-327

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.6, 2013-11, pp. : 323-327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX

By  

Oncology, Vol. 79, Iss. 1-2, 2010-12 ,pp. : 136-143

Karger

Access to resources Recommend Favorite

Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience

By  

Oncology, Vol. 76, Iss. 1, 2008-11 ,pp. : 36-41

Karger

Access to resources Recommend Favorite

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 83-89

Karger

Access to resources Recommend Favorite

Pulmonary Fibrosis after Chemotherapy with Oxaliplatin and 5-Fluorouracil for Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 270-272

Karger

Access to resources Recommend Favorite

Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 254-265

Karger

Access to resources Recommend Favorite